Base de dados : HANSEN
Pesquisa : TALIDOMIDA/FARMACOL [Descritor de assunto]
Referências encontradas : 18 [refinar]
Mostrando: 1 .. 18   no formato [Detalhado]

página 1 de 1

  1 / 18 HANSEN  
              next record last record
seleciona
para imprimir
Texto Completo-pt
Id:26027
Autor:Marques, M. B; Opromolla, Diltor Vladimir Ara£jo.
Título:A talidomida no tratamento da reação leprótica.
Fonte:Rev. bras. Leprol;37(1/4):41-49, 1970. ^btab.
Descritores:Hanseníase/quimioter
Hanseníase/imunol
Hanseníase/fisiopatol
Hanseníase/reabil
Talidomida/imunol
Talidomida/farmacol
Talidomida/uso terap
Eritema Nodoso/compl
Eritema Nodoso/fisiopatol
Limites:Humanos
Masculino
Feminino
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/brasleprol/1970/PDF/v37n1-4/v37n1-4a03.pdf - pt.
Localização:BR191.1


  2 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:25573
Autor:Teo, Steve K; Denny, Kevin H; Stirling, David I; Thomas, Steve D; Morseth, Sandy; Hoberman, Alan M
Título:Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand whith rabbits and offspring
..-
Fonte:s.l; s.n; 2004. 11 p. tab.
Resumo:The present study determined effects of thalidomide on three successive generations of New Zeland Whith rabbits after oral dosing to FO maternal rabbits during the later third of gestation (post major organogenesis) and lactation. On hundred and twenty four time-mated FO rabbits (31/dose) were gaveged with 0,030,150, or 500mg/kg thalidomide from gestation day 18 (DG 18) to lactation day 28 (DP or day postpartum 28) for approximately 42 days. At 6 months, 12 F1 females were randomly paired witthin each dose group and mated. Reproductive evaluation and/or gross necropsy of the thoracic, abodominal, and pelvic viscera was perfomed on day 29 postpartum (DP 29) for FO rabbits, on DP49 for F1 pups not selected for continued evaluation, sfter completion of mating for F1 rabbits, and on DG 29 for F1 rabbits on continued evaluation of F2 litter. There was no thalidomide-related mortality in FO and F1 rabbits. One FO doe at 30 and 150 mg/kg and 2 at 500 mg/kg aborted. Maternal FO rabbits had reductions in feed consumption but no body weight gain during the gestation and lactation periods for 150 and 500 mg/kg. The numbers of does with stillborn and all pups dyving from DP 1-4 was increased at 150 and 500 mg/kg. Mean number of liverborn (litter size) and percentage of live pups were decreased at 500 mg/kg. A significantly increased number of pups died at 150 and 500 mg/kg, resulting in a reduced viability index and decreased litter size. There were some F1 male and female bodyweight reductions at 150 and 500 mg/kg postweaning with no changein feed consumption. F1 Caesarean-sectioning and litter observations were normal. Fertility of F1 offspring was not affected by maternal doses of thalidomide, but the pregnancy index may have been reduced by the 500 mg/kg maternal thalidomide dose. There was an apparent dose-related increased in splayed limbs in F1 pups. Splaving has been reported in New Zealand Whith rabbits and may be a recessive trait. The splay could be caused by the nerve and muscle fiber degeneration and skeletal muscle atrophy observed in some pups. It could also be due to the decreased in litter size, resulting in fewer pups per litter for nursing, leading to rapid weight gain and a failure of the pups to support this weight. No F@ fetal gross external alterations were observed. (AU).
Descritores:COELHOS/anorm
COELHOS/embriol
COELHOS/cresc
TALIDOMIDA/admin
TALIDOMIDA/ef adv
TALIDOMIDA/farmacol
ABORTO ANIMAL/etiol
 PESO AO NASCER/ef drogas
Limites:COELHOS
Localização:BR191.1; 00953/s


  3 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:24991
Autor:Abreu, Luiz A; Abreu, R Raposo
Título:Talidomida efeito sobre a ceruloplasmina serica
Thalidomide: effect on the serum ceruloplasmin-
Fonte:s.l; s.n; 1966. 3 p. tab.
Resumo:Ceruloplasmin enzymatic activity was determined in rat sera using p-phenylenediamine as substrate at pH 5.4. The levels of the oxidase in the animais treated with thalidomide by perenteral or gatro-intestinal routes were not statistically different from the values obtained in the control rats.(AU).
Descritores:TALIDOMIDA/sint quim
TALIDOMIDA/farmacol
TALIDOMIDA/uso terap
CERULOPLASMINA/ef adv
CERULOPLASMINA/bios
CERULOPLASMINA/farmacol
CERULOPLASMINA/fisiol
CERULOPLASMINA/farmacocin
Limites:ESTUDO COMPARATIVO
HUMANO
Localização:BR191.1; 01064/s


  4 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:24457
Autor:Barnhill, Raymond L; McDougall, A. Colin.
Título:Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions.
Fonte:In: Sober, Arthur J; Fitzpatrick, Thomas.The year book of dermatology. Chicago, Year Book Medical Publishers, 1983. p.51-53tab.
Descritores:HANSENIASE/quimioter
TALIDOMIDA/sint quim
TALIDOMIDA/farmacol
TALIDOMIDA/uso terap
Limites:ESTUDO COMPARATIVO
Localização:BR191.1; WR100, S12y


  5 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18947
Autor:Dredge, Keith; Marriott, J. Blake; Dalgleish, Angus G
Título:Immunological effects of thalidomide and its chemical and functional analogs
..-
Fonte:s.l; s.n; 2002. 13 p. ilus, tab.
Resumo:Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer. Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-alpha, T-cell costimulatory and antiangiogenic activity. Novel compounds with improved immunomodulatory activity and side effect profiles are also being evaluated. These include selective cytokine inhibitory drugs (SelCIDs), with greatly improved TNF-alpha inhibitory activity, and immunomodulatory drugs (IMiDs) that are structural analogs of thalidomide, with improved properties. A third group recently identified within the SelCID group, with phosphodiesterase type 4-independent activity, is in the process of being characterized in laboratory studies. This review describes the emerging immunological properties of thalidomide, from a historical context to present-day clinical applications, most notably in multiple myeloma but also in other cancers, inflammatory disease, and HIV. We also describe the laboratory studies that have led to the characterization and development of SelCIDs and IMiDs into potentially clinically relevant drugs. Early trial data suggest that these novel immunomodulatory compounds may supercede thalidomide to become established therapies, particularly in certain cancers. Further evidence is required, however, to correlate the clinical efficacy of these compounds with their known immunomodulatory, antiangiogenic, and antitumor properties. (AU).
Descritores:TALIDOMIDA/analog
TALIDOMIDA/imunol
TALIDOMIDA/farmacol
SISTEMA IMUNE/ef drogas
NEOPLASIAS/quimioter
NEOPLASIAS/imunol
INFECCOES POR HIV/quimioter
INFECCOES POR HIV/imunol
ADJUVANTES IMUNOLOGICOS/farmacol
INIBIDORES DE ANGIOGÊNESE/imunol
INIBIDORES DE ANGIOGÊNESE/farmacol
ANTIVIRAIS/imunol
ANTIVIRAIS/farmacol
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 04731/s


  6 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18936
Autor:Vescovo, Giorgio; Ravara, Barbara; Angelini, Annalisa; Sandri, Marco; Carraro, Ugo; Ceconi, Claudio; Dalla Libera, Luciano
Título:Effect of thalidomide on the skeletal muscle in experimental heart failure
..-
Fonte:s.l; s.n; 2002. 6 p. ilus, tab.
Resumo:BACKGROUND: Tumour Necrosis Factor alpha (TNFalpha) has been shown to contribute to heart failure (CHF) progression. AIMS: We have tried to antagonise the detrimental effects of TNFalpha on skeletal muscle apoptosis, by using thalidomide, a drug that inhibits its biosynthesis. METHODS: CHF was induced in 20 rats by injecting monocrotaline, which determines right ventricle (RV) failure. After 2 weeks, when CHF developed, 12 rats were treated with thalidomide 3.5.mg/kg per day for 2 weeks. Eight had saline and served as CHF controls. RESULTS: Thalidomide failed to decrease TNFalpha and its second messenger sphingosine (SPH), but was able to prevent the shift toward the fast myosin heavy chains. In the Tibialis Anterior muscle of the thalidomide group, the degree of atrophy, the number of apoptotic nuclei and the levels of caspases, were similar to those of the CHF controls. CONCLUSIONS: Thalidomide, at the doses used in this study, which are the same employed for the treatment of tubercolosis, leprosy, AIDS and cancer in humans, did not lower either TNFalpha or SPH and only marginally influenced the apoptosis-induced muscle atrophy. Since other TNFalpha blockers are under investigation for improving the clinical status of patients with CHF, the present data could be relevant in the design of randomised clinical trials in humans. (AU).
Descritores:APOPTOSE/ef drogas
INSUFICIÊNCIA CARDIACA CONGESTIVA/ind quim
INSUFICIÊNCIA CARDIACA CONGESTIVA/patol
MONOCROTALINA/tox
MUSCULO ESQUELETICO/ef drogas
MUSCULO ESQUELETICO/patol
ATROFIA MUSCULAR/ind quim
ATROFIA MUSCULAR/patol
CADEIAS PESADAS DE MIOSINA/metab
RATOS SPRAGUE-DAWLEY
ESFINGOSINA/antag
ESFINGOSINA/metab
TALIDOMIDA/farmacol
FATOR DE NECROSE TUMORAL/antag
FATOR DE NECROSE TUMORAL/metab
DISFUNCAO VENTRICULAR DIREITA/ind quim
DISFUNCAO VENTRICULAR DIREITA/patol
Limites:ANIMAL
RATOS
Meio Eletrônico: - .
Localização:BR191.1; 09104/s


  7 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18472
Autor:Teo, Steve K; Resztak, Ken E; Scheffler, Michael A; Kook, Karin A; Zeldis, Jerry B; Stirling, David I; Thomas, Steve D
Título:Thalidomide in the treatment of leprosy
..-
Fonte:s.l; s.n; 2002. 10 p. ilus, tab.
Resumo:Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-alpha produced by monocytes. (AU).
Descritores:QUIMIOTERAPIA COMBINADA
ERITEMA NODOSO/quimioter
ERITEMA NODOSO/patol
INCIDÊNCIA
HANSENOSTATICOS/uso terap
HANSENIASE/quimioter
HANSENIASE/patol
HANSENIASE/transm
HANSENIASE VIRCHOWIANA/quimioter
HANSENIASE VIRCHOWIANA/patol
MODELOS MOLECULARES
MYCOBACTERIUM LEPRAE/patogen
TALIDOMIDA/ef adv
TALIDOMIDA/farmacol
TALIDOMIDA/farmacocin
TALIDOMIDA/uso terap
FATOR DE NECROSE TUMORAL/metab
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 09014/s


  8 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18410
Autor:Sheskin, Jacob
Título:The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide
..-
Fonte:s.l; s.n; july-aug. 1980. 5 p. tab.
Resumo:The history of the treatment of lepra reaction has involved the trial of many different drugs; some have proven effective and some have not. The problem has been to find a treatment with minimal side effects. This paper deals with the treatments which have been tried and the success that has been achieved with talidomide.(AU).
Descritores:IRITE/quimioter
HANSENIASE/compl
HANSENIASE/quimioter
NEURITE/quimioter
DERMATOPATIAS/quimioter
FATORES DE TEMPO
TALIDOMIDA/ef adv
TALIDOMIDA/farmacol
TALIDOMIDA/uso terap
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 00466/s


  9 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17814
Autor:Scolari, F; Harms, M; Gilardi, S
Título:La thalidomide dans le traitement du lupus érythémateux chronique
Thalidomide in the treatment of chronic lupus erythematosus-
Fonte:s.l; s.n; oct. 1982. 8 p. ilus, tab.
Resumo:The effect of thalidomide was investigated in 12 patients with chronic lupus erythematosus resistant to classical treatment (antimalarial drugs, topical steroids). 10 patients were improved and 2 were not sensitive to the treatment. The doses were 100 mg/day for a minimum period of 2 months. With the exception of 1 case, the treatment was well tolerated. The indications of thalidomide in dermatology and the mechanism of action of the drug are briefly discussed.(AU).
Descritores:DOENCA CRÔNICA
QUIMICA
LUPUS ERITEMATOSO SISTÊMICO/quimioter
LUPUS ERITEMATOSO SISTÊMICO/patol
TALIDOMIDA/farmacol
TALIDOMIDA/uso terap
Limites:HUMANO
MASCULINO
FEMININO
ADULTO
MEIA-IDADE
IDOSO
RESUMO EM INGLES
Meio Eletrônico: - .
Localização:BR191.1; 02113/s


  10 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16319
Autor:Sampaio, E. P; Hernandez, M. O; Carvalho, D. S; Sarno, E. N
Título:Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro
..-
Fonte:s.l; s.n; 2002. 7 p. ilus, graf.
Descritores:APOPTOSE
CITOCINAS
CITOCINAS
ERITEMA NODOSO
IMUNOSSUPRESSORES
IMUNOSSUPRESSORES
INTERLEUCINA-12
MONOCITOS
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
RNA MENSAGEIRO
RNA MENSAGEIRO
RNA MENSAGEIRO
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
FATOR DE NECROSE TUMORAL/AI/GE
Localização:BR191.1; 08709/s


  11 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:16014
Autor:Mujagic, Hamza; Chabner, Bruce A; Mujagic, Zlata
Título:Mechanisms of action and potential therapeutic uses of thalidomide
..-
Fonte:s.l; s.n; 2002. 12 p. tab.
Descritores:MIELOMA MULTIPLO
MIELOMA MULTIPLO
NEOPLASIAS
NEOPLASIAS
DEFEITOS DO TUBO NEURAL
DEFEITOS DO TUBO NEURAL
SENSIBILIDADE E ESPECIFICIDADE
RELAÇAO ESTRUTURA-ATIVIDADE
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
RESULTADO DE TRATAMENTO
Localização:BR191.1; 08595/s


  12 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15894
Autor:Mujagic, Hamza; Chabner, Bruce A; Mujagic, Zlata
Título:Mechanisms of action and potential therapeutic uses of thalidomide
..-
Fonte:s.l; s.n; 2002. 12 p. ilus, tab.
Descritores:ENSAIOS CLINICOS
MIELOMA MULTIPLO
MIELOMA MULTIPLO
NEOPLASIAS
NEOPLASIAS
SENSIBILIDADE E ESPECIFICIDADE
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
Localização:BR191.1; 08562/s


  13 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15733
Autor:Peuckmann, Vera; Fisch, Michael; Bruera, Eduardo
Título:Potential novel uses of thalidomide: focus on palliative care
..-
Fonte:s.l; s.n; 2000. 20 p. ilus, tab.
Descritores:HANSENIASE LEPROMATOSA
CAQUEXIA
CITOCINAS
ERITEMA NODOSO
DOENÇA ENXERTO-HOSPEDEIRO
ASSISTENCIA PALIATIVA
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
Localização:BR191.1; 08468/s


  14 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15694
Autor:Mujagic, Hamza; Chabner, Bruce A; Mujagic, Zlata
Título:Mechanisms of action and potential therapeutic uses of thalidomide
..-
Fonte:s.l; s.n; 2002. 12 p. tab.
Descritores:TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
ENSAIOS CLINICOS
MIELOMA MULTIPLO
MIELOMA MULTIPLO
NEOPLASIAS
NEOPLASIAS
DEFEITOS DO TUBO NEURAL
DEFEITOS DO TUBO NEURAL
SENSIBILIDADE E ESPECIFICIDADE
RELAÇAO ESTRUTURA-ATIVIDADE
RESULTADO DE TRATAMENTO
Localização:BR191.1; 08505/s


  15 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:15564
Autor:Liao, Adolfo Wenjaw; Ruano, Rodrigo; Bunduki, Victor; Miyadahira, Seizo; Zugaib, Marcelo
Título:Talidomida: aspectos atuais em obstetrícia
?-
Fonte:São Paulo; s.n; 1999. 4 p. tab, graf.
Descritores:TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
ANORMALIDADES INDUZIDAS POR DROGAS
HANSENIASE
COMPLICAÇOES NA GRAVIDEZ
LUPUS ERITEMATOSO SISTEMICO
ERITEMA NODOSO
TERATOGENIOS
GRAVIDEZ
CUIDADOS MEDICOS
Localização:BR191.1; 08411/s


  16 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14981
Autor:Calabrese, Leonard; Fleischer, Alan B
Título:Thalidomide: current and potential clinical applications
..-
Fonte:s.l; s.n; 2000. 9 p. tab.
Descritores:HANSENIASE LEPROMATOSA
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
ARTRITE REUMATOIDE
SINDROME DE BEHCET
AGENTES DERMATOLOGICOS
AGENTES DERMATOLOGICOS
AGENTES DERMATOLOGICOS
ECTROMELIA
ERITEMA NODOSO
DOENÇA ENXERTO-HOSPEDEIRO
INFECÇOES POR HIV
IMUNOSSUPRESSORES
IMUNOSSUPRESSORES
IMUNOSSUPRESSORES
LUPUS ERITEMATOSO CUTANEO
NEOPLASIAS
DOENÇAS DO SISTEMA NERVOSO PERIFÉRICO
ESTOMATITE AFTOSA
TERATOGENIOS
TALIDOMIDA
TALIDOMIDA
TALIDOMIDA
Localização:BR191.1; 07430/s


  17 / 18 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13870
Autor:Fernandez, Luis P; Schlegel, Paul G; Baker, Jeanette; Chen, Yanfei; Chao, Nelson J
Título:Does thalidomide affect IL-2 response and production?
..-
Fonte:s.l; s.n; 1995. 8 p. tab, graf.
Descritores:TALIDOMIDA
CÉLULAS CLONAIS
RELAÇAO DOSE-RESPOSTA A DROGA
ELEMENTOS DE FACILITAÇAO (GENÉTICA)
ELISA
RECEPTORES DA INTERLEUCINA 2
RECEPTORES DA INTERLEUCINA 2
LINFOCITOS
LINFOCITOS
TRANSFORMAÇAO LINFOCITICA
TRANSFECÇAO
CÉLULAS CULTIVADAS DE TUMOR
BETA-GALACTOSIDASE
BETA-GALACTOSIDASE
Localização:BR191.1; 06805/s


  18 / 18 HANSEN  
              first record previous record
seleciona
para imprimir
Texto Completo-Pt
Id:9113
Autor:Santos Junior, Manoel Fernando Queiroz dos; Lombardi, Clovis; Belda, Walter.
Título:Talidomida: uma revisao da literatura / Thalidomide: a revision of literature
Fonte:Hansen. Int;6(2):136-145, dez. 1981. graf.
Resumo:Procedeu-se a uma reuniao bibliografica extensiva sobre a talidomida, em seus aspectos farmacologicos, metabolicos, teratogenicidade e especialmente quanto as suas aplicacoes terapeuticas em Dermatologia, destacando-se o uso na reacao hansenica. (AU).
Descritores:HANSENIASE
HANSENIASE
TALIDOMIDA
 TALIDOMIDA
 TALIDOMIDA
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/hansenint/v01aov20/1981/PDF/v6n2/v6n2a05.pdf - Pt.
Localização:BR191.1



página 1 de 1
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information